Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Canadian Journal of Gastroenterology and Hepatology - Egypt
doi 10.1155/2016/6260271
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Reduced Risk of Hepatitis B and Hepatitis C Among Injection Drug Users in the Tacoma Syringe Exchange Program.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1995English

Injecting Risk Behaviours Following Treatment for Hepatitis C Virus Infection Among People Who Inject Drugs: The Australian Trial in Acute Hepatitis C

International Journal of Drug Policy
MedicineHealth Policy
2015English

Adjustment for Exploratory Cut‐off Selection in Randomized Clinical Trials With Survival Endpoint

Biometrical Journal
MedicineUncertaintyStatisticsProbability
2019English

Bioelectrical Impedance Analysis in Clinical Practice: Implications for Hepatitis C Therapy BIA and Hepatitis C

Virology Journal
VirologyInfectious Diseases
2010English

Hepatitis C Virus Risk Behaviors Within the Partnerships of Young Injecting Drug Users

Addiction
MedicinePsychiatryMental Health
2010English

Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2015English

Linkage to Hepatitis C Care After Incarceration in Jail: A Prospective, Single Arm Clinical Trial

BMC Infectious Diseases
Infectious Diseases
2019English

Seroepidemiology and Risk Factors of Hepatitis B and C Virus Infections Among Drug Users in Jakarta, Indonesia

Medical Journal of Indonesia
Medicine
2002English

Hepatitis C Virus and Death Risk in Hemodialysis Patients

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy